Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

The vision research community rallies to protect the National Eye Institute from funding cuts, emphasizing its vital role in preventing blindness and advancing treatments.

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

This systematic review comprehensively summarizes treatment approaches for all types of age-related macular degeneration (AMD ...

The research team used data from 1990 to 2021 to analyze the prevalence of vision loss due to macular degeneration and the resulting changes in the burden of health loss. Macular degeneration is a ...

The UC Davis Department of Ophthalmology has received a five-year, $3.6 million grant from the National Eye Institute to ...

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both ...

Hadley's Living with Macular Degeneration: A workshop series covering assistive technology, home safety, and coping strategies, grounded in research on low-vision rehabilitation.